Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Kenya Pharmaceuticals and Healthcare Report Q2 2015

Kenya Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Jan 30 2015

BMI View: The impending dual epidemic of communicable and non-communicable diseases in Kenya will
create business opportunities for multinational drugmakers. Investment into physician and patient
education and therefore addressing one of the barriers to high-quality care in an emerging economy such
as Kenya - will work to indirectly create a sales channel for their medicines, in both the public and private
sector. Furthermore, efforts to raise awareness of therapeutics and disease management will work to create

$1,295.00
South Korea Pharmaceuticals and Healthcare Report Q1 2015

South Korea Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 30 2015

BMI View: The domestic pharmaceutical industry will continue to have conflicts with the South Korean
government over price controls. As a result of these price controls, growth of the pharmaceutical market
will be limited and firms need to expand overseas to sustain their businesses.
Headline Expenditure Projections
■ Pharmaceuticals: KRW16,106.7bn (USD14.71bn) in 2013 to KRW16,590.4bn (USD15.80bn) in 2014;
+3.0% in local currency terms and +7.4% in US dollar terms. Forecast unchanged from Q414.

$1,295.00
Thailand Pharmaceuticals and Healthcare Report Q2 2015

Thailand Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Jan 30 2015

BMI View: Thailand will continue to be an attractive location to international drug makers as a result of its
growing domestic pharmaceutical market with an ageing population and improving access to healthcare as
well as its position as an entry point into the frontier markets of South East Asia. Japanese pharmaceutical
companies such as Eisai in particular, have been attracted to the market and are looking to leverage the
region's growth.
Headline Expenditure Projections

$1,295.00
Iraq Pharmaceuticals and Healthcare Report Q1 2015

Iraq Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: The competitiveness of Iraq's pharmaceutical sector, as well as the ability of the government to
ramp up healthcare investment, is linked to oil prices and additional foreign investment, which is, in turn,
highly dependent on the security situation. The long-term prospects for the Iraqi pharmaceutical and
healthcare markets therefore remain promising given rising healthcare expenditure and population growth.
The Iraqi government reportedly pledged to invest USD12bn into healthcare expansion in 2014, and the

$1,295.00
Kuwait Pharmaceuticals and Healthcare Report Q1 2015

Kuwait Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: With some of the largest financial buffers of any GCC member nation, Kuwait is well equipped
to insulate health expenditure from the near-term effects of falling oil prices. Accordingly, drugmakers can
expect high and rising underlying demand for branded prescriptions to be well sustained, due to the sector's
perception as a critical source of economic diversification away from hydrocarbons. However, recurrent
government resignations and a recent stalemate between the opposition and cabinet, resulting in major

$1,295.00
Portugal Pharmaceuticals and Healthcare Report Q1 2015

Portugal Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: The Portuguese government measures to reduce public spending on medicines will continue to
weigh on the pharmaceutical sector over a multi-quarter horizon, as illustrated by a new cost-containment
agreement between the Ministry of Health and the pharmaceutical industry. Among the agreed items, the
government commits to ensure the partial liquidation of payment arrears by public healthcare providers to
pharmaceutical suppliers over the next quarters, while the industry sector accepts to contribute to a

$1,295.00
Serbia Pharmaceuticals and Healthcare Report Q1 2015

Serbia Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: The combination of a deteriorating economic outlook, rising political risks and industryspecific
challenges place downside pressure on prospects for Serbia's pharmaceutical market. In light of
this situation, we do not expect any meaningful investments by foreign firms. The key commercial
opportunity is locally-made generic drugs.
Headline Expenditure Projections
Pharmaceuticals: RSD90.46bn (USD1.06bn) in 2013 to RSD99.03bn (USD1.13bn) in 2014; +9.5% in

$1,295.00
Sri Lanka Pharmaceuticals and Healthcare Report Q1 2015

Sri Lanka Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: Sri Lanka's improvements in healthcare have created stronger commercial opportunities for
drugmakers in the country, which is also experiencing an epidemiological shift towards chronic diseases.
However, strong reliance on foreign aid as well as medicine price caps will limit increases in revenueearning
opportunities.
Headline Expenditure Projections
■ Pharmaceuticals: LKR67.70bn (USD524mn) in 2013, to LKR75.09bn (USD570mn) in 2014; +10.9% in
local currency terms and 8.9% in US dollar terms over the five-year forecast period.

$1,295.00
Uzbekistan Pharmaceuticals and Healthcare Report Q1 2015

Uzbekistan Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: Economic growth will allow the Uzbek government to sustain the expansive trend in healthcare
investment and expenditure over the next years. Rising wages and private consumption will also contribute
to drive pharmaceutical and healthcare sector growth, albeit from a low base. Despite recent steps by the
Uzbek government to improve business operating legislation and attract foreign technology transfer in
pharmaceutical production projects, restrictive capital controls and poor governance will continue to weigh

$1,295.00
Venezuela Pharmaceuticals and Healthcare Report Q1 2015

Venezuela Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: New trade and cooperative agreements for necessary medicines as well as financial injections
into the healthcare system will ease Venezuela's troublesome medicine shortage as well as expand
healthcare provision in the short-term. Though, the country's fundamental problems which include an
increasing inflation, currency devaluation, and a problematic desire for pharmaceutical self-reliance will
continue to significantly impair the development of Venezuela's pharmaceutical and healthcare markets
over the long-term.

$1,295.00
Vietnam Pharmaceuticals and Healthcare Report Q1 2015

Vietnam Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: With a growing and ageing population, Vietnam plays host to an attractive target for
pharmaceutical and healthcare growth. While per capita spending remains low, and current healthcare
infrastructure appears strained, access to healthcare coverage is steadily increasing.
Headline Expenditure Projections
■ Pharmaceuticals: VND69,297bn (USD3.30bn) in 2013 to VND80,730bn (USD3.80bn) in 2014; +17.0%
in local currency terms and +16.2% in US dollar terms. Forecast unchanged from previous quarter.

$1,295.00
Chile Pharmaceuticals and Healthcare Report Q1 2015

Chile Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: Well into our extended forecast period, market conditions in Chile remain very attractive for
multinational drugmakers. Although cost containment and measures to promote the uptake of generics are
ongoing, the pace of reform is slow and entrants will continue to enjoy a relatively flexible operating
environment. Notably, the private sector, which constitutes a disproportionate share of total spending, is
markedly less price sensitive than public consumers and will continue to exhibit strong bias towards

$1,295.00
Greece Pharmaceuticals and Healthcare Report Q1 2015

Greece Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Jan 21 2015

BMI View: A distinct escalation in political uncertainty will see continued erosion of public and political
support for the implementation of much-needed reforms. In addition, drugmakers will see revenue
opportunities constrained as pressures on Greek household spending are amplified by an anachronistic and
distorted domestic pharmaceutical reimbursement structure. Regressive funding, under-the-table payments
and the lack of universal healthcare administration have allowed numerous intermediaries to operate

$1,295.00
Dietary Supplements: World of Opportunities In the Indian Healthcare Market

Dietary Supplements: World of Opportunities In the Indian Healthcare Market

Date Published: Jan 20 2015
Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention.  These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain – ‘Nutraceuticals’.  Over the years, nutraceutical market has experienced robust growth fueled by high consumer demand, product innovation and low regulatory hurdles.  The nutraceutical industry is already facing intense competitive pressure wherein companies are seeking new opportunities or geography expansion in the functional fo
$2,000.00
Home Health Care Services World Report

Home Health Care Services World Report

Date Published: Jan 15 2015

HOME HEALTH CARE SERVICES WORLD REPORT

The Home Health Care Services World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00
Offices of Dentists Lines World Report

Offices of Dentists Lines World Report

Date Published: Jan 15 2015

OFFICES OF DENTISTS LINES WORLD REPORT

The Offices of Dentists Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00
Speech Therapists & Audiologists Lines World Report

Speech Therapists & Audiologists Lines World Report

Date Published: Jan 15 2015

SPEECH THERAPISTS & AUDIOLOGISTS LINES WORLD REPORT

The Speech Therapists & Audiologists Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00
Specialty Hospital Lines World Report

Specialty Hospital Lines World Report

Date Published: Jan 15 2015

SPECIALTY HOSPITAL LINES WORLD REPORT

The Specialty Hospital Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00
Outpatient Care Centers Miscellaneous Lines World Report

Outpatient Care Centers Miscellaneous Lines World Report

Date Published: Jan 15 2015

OUTPATIENT CARE CENTERS MISCELLANEOUS LINES WORLD REPORT

The Outpatient Care Centers Miscellaneous Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00
Miscellaneous Ambulatory Health Care Service Lines World Report

Miscellaneous Ambulatory Health Care Service Lines World Report

Date Published: Jan 15 2015

MISCELLANEOUS AMBULATORY HEALTH CARE SERVICE LINES WORLD REPORT

The Miscellaneous Ambulatory Health Care Service Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: From 1997- 2015 and Forecasts 2016- 2023 & 2023-2028.

$2,950.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data